If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
28th Feb 20259:43 amRNSDirector/PDMR Shareholding
28th Feb 20259:42 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSHolding(s) in Company
27th Feb 20254:31 pmRNSDirector/PDMR Shareholding
27th Feb 20254:29 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSJoseph Ciaffoni Appointed Chief Executive Officer
25th Feb 20257:00 amRNSHolding(s) in Company
24th Feb 20257:00 amRNSFDA Approval of SUBLOCADE Label Changes
20th Feb 20257:00 amRNSFinal Results
12th Feb 20257:00 amRNSDelayed FDA Approval of SUBLOCADE Label Changes
4th Feb 20253:12 pmRNSNotice of Results
4th Feb 20257:00 amRNSCompletion of Share Repurchase Program
4th Feb 20257:00 amRNSTransaction in Own Shares
3rd Feb 20259:26 amRNSTotal Voting Rights
3rd Feb 20257:00 amRNSAppointment of Independent Non-Executive Director
28th Jan 20253:30 pmRNSDr. David Wheadon appointed Chair of the Board
28th Jan 20259:43 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSTransaction in Own Shares
27th Jan 20259:08 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTransaction in Own Shares
16th Jan 20254:00 pmRNSReplacement Transaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20251:00 pmRNSIndivior Provides Historical Financials in US GAAP
7th Jan 20258:55 amRNSHolding(s) in Company
7th Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20259:31 amRNSTotal Voting Rights
31st Dec 20249:53 amRNSHolding(s) in Company
31st Dec 20247:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 202410:32 amRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSIndivior Announces Changes to Board of Directors
17th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20249:44 amRNSTotal Voting Rights
26th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSIndivior to Participate in Upcoming Investor Event
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20248:48 amRNSHolding(s) in Company
15th Nov 20247:00 amRNSDirector Declaration
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20242:29 pmRNSHolding(s) in Company
8th Nov 20244:50 pmRNSBlock listing Interim Review
8th Nov 20247:00 amRNSIndivior Responds to Letter from Oaktree
5th Nov 20247:00 amRNSIndivior Completes Refinance of Secured Term Loan
5th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 202411:59 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares
24th Oct 20247:00 amRNS3rd Quarter Results
22nd Oct 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.